Literature DB >> 24827764

Peripheral B-cell phenotype and BAFF levels are associated with HLA immunization in patients awaiting kidney transplantation.

Renaud Snanoudj1, Sophie Candon, Dave L Roelen, Jean-Philippe Jais, Frans H Claas, Christophe Legendre, Lucienne Chatenoud.   

Abstract

BACKGROUND: The role of B-cell subsets in human leukocyte antigen (HLA)-specific humoral responses in patients with end-stage renal disease is poorly documented. The objective of this study was to analyze the potential association between B-cell subsets distribution and anti-HLA antibodies before kidney transplantation.
METHODS: The authors studied by flow cytometry peripheral B-cell subsets and serum levels of BAFF, the main homeostatic cytokine for peripheral B cells, in 101 consecutive end-stage renal disease patients admitted for transplantation.
RESULTS: In patients with HLA antibodies detected with Luminex single antigen, the proportion of activated naive B cells (Bm2) was significantly higher (64.4 ± 15.1% vs. 52.5 ± 19.1% in HLA antibody-negative patients, P=0.0008) at the expense of memory B cells, as were BAFF serum levels (1,651 ± 1,297 vs. 1,139 ± 693 pg/mL, P<0.0001). Proportion of Bm2 and BAFF levels were positively associated with the diversity of anti-HLA antibodies. In multivariate analysis, besides HLA-immunizing events (pregnancy and previous transplantation), proportion of Bm2 cells but not of other B-cell subsets or BAFF levels was independently associated with the presence and diversity of anti-HLA antibodies. High proportion of Bm2 cells before transplantation was associated with an increased risk of developing de novo donor-specific antibodies during the first year posttransplant. The authors did not find any association between the frequency of antibody-mediated rejection and pretransplant proportion of any B-cell subset or BAFF serum levels.
CONCLUSION: Increased proportions of activated naive B cells are linked with pretransplant HLA immunization and the development of posttransplant donor-specific antibodies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24827764     DOI: 10.1097/01.TP.0000438211.34842.5e

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

Review 1.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

2.  Biomarkers in kidney transplantation: From bench to bedside.

Authors:  Natavudh Townamchai; Somchai Eiam-Ong
Journal:  World J Nephrol       Date:  2015-11-06

3.  Anti-BAFF Therapy: A New Tool to Target B Cells in Antibody-mediated Rejection?

Authors:  Sarah E Panzer
Journal:  Transplantation       Date:  2020-01       Impact factor: 5.385

Review 4.  B Cell Immunity in Solid Organ Transplantation.

Authors:  Gonca E Karahan; Frans H J Claas; Sebastiaan Heidt
Journal:  Front Immunol       Date:  2017-01-10       Impact factor: 7.561

5.  B-Cell Activating Factor Predicts Acute Rejection Risk in Kidney Transplant Recipients: A 6-Month Follow-Up Study.

Authors:  Xu-Zhen Wang; Zhen Wan; Wu-Jun Xue; Jin Zheng; Yang Li; Chen Guang Ding
Journal:  Front Immunol       Date:  2019-05-15       Impact factor: 7.561

6.  Phenotypic and Transcriptomic Lymphocytes Changes in Allograft Recipients After Intravenous Immunoglobulin Therapy in Kidney Transplant Recipients.

Authors:  Caroline Pilon; Jeremy Bigot; Cynthia Grondin; Allan Thiolat; Philippe Lang; José L Cohen; Philippe Grimbert; Marie Matignon
Journal:  Front Immunol       Date:  2020-01-24       Impact factor: 7.561

7.  Investigating the Role of BAFF and Its Receptors in Renal Transplant Recipients with Chronic Antibody-Mediated Rejection.

Authors:  Shima Afzali; Saeedeh Salehi; Abbas Shahi; Marzie Esmaeili; Samad Farashi Bonab; Azin Peykari; Farzaneh Bagherpour; Bita Ansaripour; Tayebeh Soleimanian; Fatemeh Pour-Reza-Gholi; Aliakbar Amirzargar
Journal:  J Immunol Res       Date:  2021-03-06       Impact factor: 4.818

8.  B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation.

Authors:  Antonia Margarete Schuster; N Miesgang; L Steines; C Bach; B Banas; T Bergler
Journal:  Immunol Res       Date:  2021-08-10       Impact factor: 2.829

Review 9.  Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review.

Authors:  Priscila Ferreira Slepicka; Mahboubeh Yazdanifar; Alice Bertaina
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.